Visit
for coverage from TIME, Health, Fortune and more
GO »
Vanity Fair New Establishment Summit - Day 1
Theranos CEO Elizabeth Holmes Photograph by Michael Kovac — Getty Images for Vanity Fair

Walgreens Trashes Theranos in Their Fiery $140 Million Lawsuit Battle

Nov 16, 2016

Walgreens' legal fight with embattled blood testing upstart Theranos was never going to be pretty. Now, we have some clues as to exactly how ugly it's going to get.

News broke last week that the drugstore giant had filed suit against Elizabeth Holmes' now-hobbled unicorn for breach of contact. The two firms were former partners, with Walgreens providing Theranos' finger-prick blood test services at 40 of its "Wellness Centers" in Arizona and California.

But as investigative reports by media outlets, inquiries by Congressional lawmakers, consumer lawsuits, and regulatory sanctions began to pile up surrounding the validity of Theranos' technological claims and deficiencies in its labs—which some feared could pose "immediate jeopardy" to patients—Walgreens scuttled the agreement. (Read Fortune's timeline of Theranos and CEO Holmes' saga here.)

Click here to subscribe to Brainstorm Health Daily, our brand new newsletter about health innovations.

Walgreens' (wba) complaint against the company from last week was sealed, so details were sparse. But the public version of the complaint (which is somewhat redacted) has now been released.

And the pharmacy chain claims that it had been consistently misled by Theranos—which allegedly didn't even inform Walgreens that 31,000 of the blood test results provided to its customers were voided until June 11. In fact, Walgreens says it only found out about these voided tests through media reports. The firm pulled out of its Theranos deal one day later after the confirmation.

Theranos eventually decided to shut down its clinical lab operations and focus on developing a new portable blood testing device called the "miniLab," during a presentation by Holmes that was afterward labeled by some as a "bait-and-switch."

Fortune has reached out to Theranos about the validity of the specific lawsuit allegations and will update this post if it responds. The company did issue a statement last Tuesday addressing the complaint, arguing that Walgreens' decision to pull out of the collaboration was in and of itself a dereliction, which made it impossible for Theranos to maintain its clinical labs.

"Over the years, Walgreens consistently failed to meet its commitments to Theranos," read the statement.

"Through its mishandling of our partnership and now this lawsuit, Walgreens has caused Theranos and its investors significant harm. We will respond vigorously to Walgreens’ unfounded allegations, and will seek to hold Walgreens responsible for the damage it has caused to Theranos and its investors."

All products and services featured are based solely on editorial selection. FORTUNE may receive compensation for some links to products and services on this website.

Quotes delayed at least 15 minutes. Market data provided by Interactive Data. ETF and Mutual Fund data provided by Morningstar, Inc. Dow Jones Terms & Conditions: http://www.djindexes.com/mdsidx/html/tandc/indexestandcs.html. S&P Index data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions